Detalles de la búsqueda
1.
Sugammadex for reversal of neuromuscular blockade in pediatric patients: Results from a phase IV randomized study.
Paediatr Anaesth;
32(3): 436-445, 2022 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-34878707
2.
Effects of Bedtime Dosing With Suvorexant and Zolpidem on Balance and Psychomotor Performance in Healthy Elderly Participants During the Night and in the Morning.
J Clin Psychopharmacol;
41(4): 414-420, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34181362
3.
Use of the single-item Patient Global Impression-Severity scale as a self-reported assessment of insomnia severity.
J Sleep Res;
30(1): e13141, 2021 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-33210445
4.
Pilot evaluation of a consumer wearable device to assess sleep in a clinical polysomnography trial of suvorexant for treating insomnia in patients with Alzheimer's disease.
J Sleep Res;
30(6): e13328, 2021 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34340251
5.
Actual versus ideal body weight dosing of sugammadex in morbidly obese patients offers faster reversal of rocuronium- or vecuronium-induced deep or moderate neuromuscular block: a randomized clinical trial.
BMC Anesthesiol;
21(1): 62, 2021 02 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-33639839
6.
A randomized trial evaluating the safety profile of sugammadex in high surgical risk ASA physical class 3 or 4 participants.
BMC Anesthesiol;
21(1): 259, 2021 10 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-34711192
7.
The Discovery of Suvorexant, the First Orexin Receptor Drug for Insomnia.
Annu Rev Pharmacol Toxicol;
57: 509-533, 2017 01 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-27860547
8.
Polysomnographic assessment of suvorexant in patients with probable Alzheimer's disease dementia and insomnia: a randomized trial.
Alzheimers Dement;
16(3): 541-551, 2020 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-31944580
9.
Orexin receptor antagonists for the treatment of insomnia and potential treatment of other neuropsychiatric indications.
J Sleep Res;
28(2): e12782, 2019 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-30338596
10.
Phase II Proof-of-Concept Trial of the Orexin Receptor Antagonist Filorexant (MK-6096) in Patients with Major Depressive Disorder.
Int J Neuropsychopharmacol;
20(8): 613-618, 2017 08 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28582570
11.
Suvorexant in Elderly Patients with Insomnia: Pooled Analyses of Data from Phase III Randomized Controlled Clinical Trials.
Am J Geriatr Psychiatry;
25(7): 791-802, 2017 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-28427826
12.
A Phase II Dose-Ranging Study Evaluating the Efficacy and Safety of the Orexin Receptor Antagonist Filorexant (MK-6096) in Patients with Primary Insomnia.
Int J Neuropsychopharmacol;
19(8)2016 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-26979830
13.
Randomized controlled trial of the orexin receptor antagonist filorexant for migraine prophylaxis.
Cephalalgia;
35(5): 379-88, 2015 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-25106663
14.
Comparison of polysomnography in people with Alzheimer's disease and insomnia versus non-demented elderly people with insomnia.
Sleep Med;
101: 515-521, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36529106
15.
A Randomized, placebo-controlled, crossover pilot trial of the oral selective NR2B antagonist MK-0657 in patients with treatment-resistant major depressive disorder.
J Clin Psychopharmacol;
32(4): 551-7, 2012 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-22722512
16.
Burden of Insomnia and Sleep Disturbances and the Impact of Sleep Treatments in Patients with Probable or Possible Alzheimer's Disease: A Structured Literature Review.
J Alzheimers Dis;
86(1): 83-109, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35001893
17.
Pharmacokinetics of Sugammadex Dosed by Actual and Ideal Body Weight in Patients With Morbid Obesity Undergoing Surgery.
Clin Transl Sci;
14(2): 737-744, 2021 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-33278332
18.
How well can a large number of polysomnography sleep measures predict subjective sleep quality in insomnia patients?
Sleep Med;
67: 137-146, 2020 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-31926466
19.
Single-dose administration of MK-0657, an NR2B-selective NMDA antagonist, does not result in clinically meaningful improvement in motor function in patients with moderate Parkinson's disease.
J Clin Pharmacol;
49(7): 856-64, 2009 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-19491335
20.
Effects of suvorexant on the Insomnia Severity Index in patients with insomnia: analysis of pooled phase 3 data.
Sleep Med;
56: 219-223, 2019 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-30522875